Showing 4691-4700 of 8095 results for "".
- Cassiopea Scores FDA Approval for Winlevi (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptorhttps://practicaldermatology.com/news/cassiopea-scores-fda-approval-for-winlevi-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor/2460513/The FDA has approved Winlevi (clascoterone cream 1%) for the treatment of acne in patients 12 years and older. "Th
- Positive Phase 3 Results for Dermavant's Tapinarof Cream for Plaque Psoriasishttps://practicaldermatology.com/news/positive-phase-3-results-results-for-dermavants-tapinarof-cream-for-plaque-psoriasis/2460511/Dermavant Sciences shared positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% in adult patients with plaque psoriasis. In both PSOARING 1 (N
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- Lumenis Introduces NuEra Tighthttps://practicaldermatology.com/news/lumenis-introduces-nuera-tight/2460502/Lumenis is rolling out the NuEra Tight with FocalRF technology for body contouring. NuEra Tight will be available worldwide starting with the United States in August 2020 and Europe, the Middle East and Asia later this year. "Radio Frequency treatments are among the most
- InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technologyhttps://practicaldermatology.com/news/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology/2460501/InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform. Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu
- SoftWave Tissue Regeneration Technologies Takes On Cellulitehttps://practicaldermatology.com/news/softwave-tissue-regeneration-technologies-takes-on-cellulite/2460494/SoftWave Tissue Regeneration Technologies plans to start a 60-patient study to evaluate the safety and efficacy of the DermaGold device for the temporary improvement in the appearance of cellulite. The company has a pa
- New Dermatology Atlas to Highlight and Compare Features of Common Dermatologic Conditions in Different Skin Typeshttps://practicaldermatology.com/news/new-dermatology-atlas-to-highlight-and-compare-features-of-common-dermatologic-conditions-in-different-skin-types/2460491/Leaders from academic dermatology and education are joining together to create a comprehensive dermatology atlas to address what they say has become a well-documented gap in dermatology education. The atlas will display side-by-side images of the most common dermatology conditions in the full spe
- FDA Fast Tracks Leo Pharma’s Delgocitinib Cream for Hand Eczemahttps://practicaldermatology.com/news/fda-fast-tracks-leo-pharmas-delgocitinib-cream-for-hand-eczema/2460490/Delgocitinib cream, Leo Pharma’s investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are curr
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti